Sallinen V, Sirén J, Mäkisalo H, Lehtimäki T E, Lantto E, Kokkola A, Nordin A
Department of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Department of Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Scand J Surg. 2020 Sep;109(3):219-227. doi: 10.1177/1457496919832150. Epub 2019 Feb 21.
Perihilar cholangiocarcinoma and distal cholangiocarcinoma arise from the same tissue but require different surgical treatment methods. It remains unclear whether these cholangiocarcinoma types have different outcomes, prognostic factors, and/or recurrence patterns.
This retrospective study evaluated patients who underwent curative-intent resection for perihilar cholangiocarcinoma or distal cholangiocarcinoma at a tertiary academic hospital during 2000-2015. Survival and prognostic factors were identified using Kaplan-Meier and Cox regression analyses.
The 90-day mortality rates were 0% for perihilar cholangiocarcinoma (36 patients) and 4% for distal cholangiocarcinoma (47 patients). There were no significant differences between perihilar cholangiocarcinoma or distal cholangiocarcinoma in median overall survival (30.9 vs 40.4 months) or median disease-free survival (14.2 vs 21.4 months). Among perihilar cholangiocarcinoma patients, age > 65 years was an independent predictor of poorer overall survival (hazard ratio: 2.45, 95% confidence interval: 1.07-5.64), while requiring bile duct re-resection was an independent predictor of disease-free survival (hazard ratio: 2.76, 95% confidence interval: 1.01-7.51). Among distal cholangiocarcinoma patients, a pN1 category independently predicted poorer overall survival (hazard ratio: 3.40, 95% confidence interval: 1.14-10.11), while preoperative CA19-9 levels >30 U/mL (hazard ratio: 2.51, 95% confidence interval: 1.09-5.79) and pN1 category (hazard ratio: 2.51, 95% confidence interval: 1.09-5.79) predicted a shorter disease-free survival. Local recurrence was more common with perihilar cholangiocarcinoma (50% of recurrences), while multiple synchronous sites were more common for distal cholangiocarcinoma (41% of recurrences).
Perihilar cholangiocarcinoma and distal cholangiocarcinoma patients have similar survival outcomes. However, local control appears to be more prognostic for perihilar cholangiocarcinoma patients, while positive lymph nodes are critical prognostic factor for distal cholangiocarcinoma patients.
肝门部胆管癌和远端胆管癌起源于相同组织,但需要不同的手术治疗方法。目前尚不清楚这些胆管癌类型是否具有不同的预后、预后因素和/或复发模式。
这项回顾性研究评估了2000年至2015年期间在一家三级学术医院接受根治性切除的肝门部胆管癌或远端胆管癌患者。使用Kaplan-Meier和Cox回归分析确定生存和预后因素。
肝门部胆管癌(36例患者)的90天死亡率为0%,远端胆管癌(47例患者)为4%。肝门部胆管癌和远端胆管癌在中位总生存期(30.9个月对40.4个月)或中位无病生存期(14.2个月对21.4个月)方面无显著差异。在肝门部胆管癌患者中,年龄>65岁是总生存期较差的独立预测因素(风险比:2.45,95%置信区间:1.07-5.64),而需要再次胆管切除是无病生存期的独立预测因素(风险比:2.76,95%置信区间:1.01-7.51)。在远端胆管癌患者中,pN1分期独立预测总生存期较差(风险比:3.40,95%置信区间:1.14-10.11),而术前CA19-9水平>30 U/mL(风险比:2.51,95%置信区间:1.09-5.79)和pN1分期(风险比:2.51,95%置信区间:1.09-5.79)预测无病生存期较短。肝门部胆管癌局部复发更常见(占复发的50%),而远端胆管癌多同步部位复发更常见(占复发的41%)。
肝门部胆管癌和远端胆管癌患者的生存结果相似。然而,局部控制似乎对肝门部胆管癌患者的预后更重要,而阳性淋巴结是远端胆管癌患者的关键预后因素。